digitalhealth



ZOË BLAKE

CEO, CARELOOP HEALTH



Stage Sponsor:




A DTx for Psychosis & Schizophrenia

Supporting Self-Management Predicting & Preventing Relapse










Psychosis & Schizophrenia in the UK

- 1% of the population will experience psychosis
- <u>80%</u> will <u>relapse within 5 years</u>
- Average life expectancy <u>15 to 20 years less</u> than general population
- Highest prevalence in most deprived inner-city areas & minority ethnic groups
- Far more likely to be unemployed, at risk of self harm and suicidal behaviour
- 220,000 receiving treatment today
- Schizophrenia care takes 30% of adult MH spend, and 75% of MH inpatient beds
- Around <u>4% of the total NHS budget (~£4bn)</u>
- Current care models don't monitor for early signs of relapse which typically last 3-10 days



Active Symptom Monitoring



Early Warning Signals



Remote Monitoring



0

The Lancet Psychiatry, 2022

Our Journey to becoming a DTx

Developed in the NHS. Co-designed at every stage. 10+ years of research. 5 gold standard RCTs

"...CareLoop may enable earlier treatment, which could reduce hospitalisations and demand on crisis intervention services"

NICE EVA, Final guidance due 27 March 2024




50% fewer relapse episodes

15wks longer to first relapse

Patients less fearful ofrelapse

High adherence - 75% for 12 months



14.3% less health professional time

33% cost reduction for hospital admissions

ICER of £3,041

NICE

ORCHA

Medical Research

Council

UK CA

National Institute for Health Research











SUPPORTED BY

w: careloop.health e: zoe@careloop.health

